Welcome to our dedicated page for Immunogen news (Ticker: IMGN), a resource for investors and traders seeking the latest updates and insights on Immunogen stock.
Immunogen Inc (IMGN) is a clinical-stage biotechnology leader pioneering targeted cancer therapies through its proprietary antibody-drug conjugate (ADC) technology. This dedicated news hub provides investors and industry professionals with timely updates on IMGN's scientific advancements, regulatory milestones, and strategic partnerships.
Our curated collection offers immediate access to official press releases, clinical trial developments, and collaboration announcements. Users will find updates on oncology research progress, FDA interactions, and technology licensing agreements that shape IMGN's position in the biopharmaceutical landscape.
Key content types include pipeline advancements for solid tumor treatments, partnership expansions with major pharmaceutical companies, and financial disclosures. The platform serves as a reliable resource for understanding how IMGN's ADC platform addresses complex oncology challenges through precision-targeted therapeutics.
Bookmark this page for streamlined tracking of IMGN's scientific and corporate developments. Combine these updates with Stock Titan's analysis tools to monitor the company's progress in transforming cancer treatment paradigms.
ImmunoGen Inc. (Nasdaq: IMGN) announced on March 31, 2021, that it granted non-qualified stock options for 29,500 shares of common stock to two new employees as part of its Inducement Equity Incentive Plan. This action complies with Nasdaq Listing Rule 5635(c)(4). The options have an exercise price of $8.10 per share, equal to the closing price on the grant date. The options will vest over four years, beginning with 25% vesting after one year and the remainder vesting quarterly, contingent on ongoing employment.
ImmunoGen Inc. announced on February 26, 2021, that its Board of Directors granted non-qualified stock options to purchase 66,500 shares of common stock to two new employees as an inducement under the Inducement Equity Incentive Plan. The options have an exercise price of $8.75 per share, aligning with the closing stock price on the grant date. The options will vest over four years, with 25% vesting on the one-year anniversary and 6.25% vesting quarterly thereafter, contingent on continued employment. This initiative aims to enhance recruitment of essential talent within the growing field of antibody-drug conjugates.
ImmunoGen Inc. (Nasdaq: IMGN) announced participation in a fireside chat at the H.C. Wainwright Virtual Global Life Sciences Conference, scheduled for March 9, 2021, at 7:00 a.m. ET. Chief Financial Officer Susan Altschuller and Chief Medical Officer Anna Berkenblit will represent the company. The presentation will be available on-demand and can be accessed via the Investors and Media section of the company's website. ImmunoGen is focused on developing next-generation antibody-drug conjugates aimed at improving cancer treatment outcomes and enhancing patient quality of life.
ImmunoGen Inc. (Nasdaq: IMGN) reported significant progress and financial results for the year ended December 31, 2020. CEO Mark Enyedy highlighted transformative advancements, including the pivotal SORAYA and MIRASOL trials for mirvetuximab soravtansine, and the Breakthrough Therapy designation for IMGN632. The company added over $140 million to its balance sheet in Q4, positioning itself for potential product launches in 2022. Upcoming milestones include top-line data in Q3 2021 and submissions for biologics licenses.
ImmunoGen Inc. (Nasdaq: IMGN) announced participation in the SVB Leerink 10th Annual Global Healthcare Conference on February 25, 2021, at 3:40 PM ET. Chief Financial Officer Susan Altschuller and Chief Medical Officer Anna Berkenblit will engage in a fireside chat. A live webcast will be accessible via the company’s website, with a replay available afterward. ImmunoGen specializes in developing next-generation antibody-drug conjugates aimed at improving cancer treatment outcomes by offering enhanced anti-tumor activity and better tolerability.
ImmunoGen Inc. (Nasdaq: IMGN) announced on January 29, 2021, the grant of non-qualified stock options to two new employees totaling 83,600 shares under its Inducement Equity Incentive Plan. The options, with an exercise price of $7.13 per share, equal the closing price on the grant date. Vesting occurs over four years, with 25% vesting after one year and 6.25% quarterly thereafter, based on continued employment status. This program complies with Nasdaq Listing Rule 5635(c)(4) and aims to attract talent as ImmunoGen advances its antibody-drug conjugate therapies for improved cancer treatment.
ImmunoGen Inc. (Nasdaq: IMGN) is set to host a conference call on February 12, 2021, at 8:00 a.m. ET to discuss its 2020 operating results and provide a business update. Interested parties can join the call by dialing (877) 621-5803, with the conference ID 1666147, or access it through the company's website. ImmunoGen focuses on developing next-generation antibody-drug conjugates (ADCs) aimed at improving cancer treatment outcomes by offering therapies with enhanced anti-tumor activity.
ImmunoGen announced the granting of non-qualified stock option awards for 91,800 shares to two new employees on December 31, 2020, under the Inducement Equity Incentive Plan. The stock options, exercisable at $6.45, equal the closing stock price on the grant date. These options will vest over four years, starting with 25% on the first anniversary. The Inducement Plan is designed for new hires as an incentive for joining the company.
ImmunoGen Inc. (Nasdaq: IMGN) announced that CEO Mark Enyedy will present at the 39th Annual J.P. Morgan Virtual Healthcare Conference on January 13, 2021, at 10:50 AM ET. Following the presentation, a Q&A session will take place at 11:10 AM ET, featuring Enyedy and management. A live webcast of both events will be accessible via the Investors & Media section on ImmunoGen's website, with a replay available afterward. ImmunoGen specializes in developing advanced antibody-drug conjugates aimed at improving cancer patient outcomes.
ImmunoGen Inc. (Nasdaq: IMGN) presented new findings on IMGN632, a CD123-targeting ADC, at the 62nd ASH Annual Meeting. The data, from the Phase 1/2 expansion study in relapsed/refractory BPDCN patients, showed a 29% overall response rate and an 18% complete remission rate with a favorable safety profile. Notably, IMGN632 exhibited no treatment-related deaths. Ongoing enrollment continues for both frontline and relapsed/refractory BPDCN patients. The company is also advancing combination studies in relapsed/refractory AML, supported by promising preclinical data.
